 CytoDyn Inc. OTCQB:CYDY has announced that its contract research organization CRO in Brazil, Albert Einstein Israelite Hospital, has met with the Brazilian Health Regulatory Agency ANVISA and received its agreement to modify the CD16 trial for critically ill coronavirus COVID-19 patients. Following ANVISAs authorization, the company said it will submit the revised protocol for CD16 providing for a reduction in total enrollment from 330 to 126 patients, with interim efficacy analysis by a data safety monitoring board DSMB after 40 of patients are enrolled and have completed follow-up to Day 28. 